Pfizer and BioNTech Update COVID-19 Vaccine Supply Agreement with EC
The companies have reached an agreement with the European Commission to update their COVID-19 vaccine supply agreement.
Pfizer and BioNTech announced on May 13, 2022 that they have reached an agreement with the European Commission (EC) to update their COVID-19 vaccine supply agreement. The update includes rephased planned deliveries to help support the EC and Member States’ immunization programs.
Doses that were scheduled for delivery in June through August 2022 will now be delivered in September through fourth quarter 2022. The delivery schedule change does not affect the companies’ full-year 2022 revenue guidance or the full-year commitment of doses to be delivered to the EC Member States in 2022.
The companies are continuing to evaluate potential variant-based vaccines and expect to share data in the coming months. The Pfizer-BioNTech COVID-19 vaccine is currently authorized under Emergency Use Authorization in individuals five years of age and older.
Source: Pfizer
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
